Cargando…

Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent

The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravoori, M. K., Singh, S., Bhavane, R., Sood, A. K., Anvari, B., Bankson, J., Annapragada, A., Kundra, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177955/
https://www.ncbi.nlm.nih.gov/pubmed/28004770
http://dx.doi.org/10.1038/srep38991
_version_ 1782485088422854656
author Ravoori, M. K.
Singh, S.
Bhavane, R.
Sood, A. K.
Anvari, B.
Bankson, J.
Annapragada, A.
Kundra, V.
author_facet Ravoori, M. K.
Singh, S.
Bhavane, R.
Sood, A. K.
Anvari, B.
Bankson, J.
Annapragada, A.
Kundra, V.
author_sort Ravoori, M. K.
collection PubMed
description The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian tumors in the peritoneal cavity by multimodal MR and near infra-red imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.05, n = 6). As seen on open abdomen and excised tumors views and confirmed by optical radiant efficiency measurement, Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p < 0.05, n = 6). This suggests clinical potential to localize ovarian tumors by MR for staging and surgical planning, and, by NIR at surgery for resection.
format Online
Article
Text
id pubmed-5177955
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51779552016-12-29 Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent Ravoori, M. K. Singh, S. Bhavane, R. Sood, A. K. Anvari, B. Bankson, J. Annapragada, A. Kundra, V. Sci Rep Article The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian tumors in the peritoneal cavity by multimodal MR and near infra-red imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.05, n = 6). As seen on open abdomen and excised tumors views and confirmed by optical radiant efficiency measurement, Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p < 0.05, n = 6). This suggests clinical potential to localize ovarian tumors by MR for staging and surgical planning, and, by NIR at surgery for resection. Nature Publishing Group 2016-12-22 /pmc/articles/PMC5177955/ /pubmed/28004770 http://dx.doi.org/10.1038/srep38991 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Ravoori, M. K.
Singh, S.
Bhavane, R.
Sood, A. K.
Anvari, B.
Bankson, J.
Annapragada, A.
Kundra, V.
Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title_full Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title_fullStr Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title_full_unstemmed Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title_short Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
title_sort multimodal magnetic resonance and near-infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode-dual-gadolinium liposomal contrast agent
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177955/
https://www.ncbi.nlm.nih.gov/pubmed/28004770
http://dx.doi.org/10.1038/srep38991
work_keys_str_mv AT ravoorimk multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT singhs multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT bhavaner multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT soodak multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT anvarib multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT banksonj multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT annapragadaa multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent
AT kundrav multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent